We thus tested the effects of CB839, a GLS inhibitor that is already in early clinical trials in kidney and breast cancer (Gross et al, 2014; Raczka and Reynolds, 2019), on the SW48 isogenic panel. This evidence concerns the gene GLS and breast cancer.